Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.
about
Antithrombin III for critically ill patientsTreatment for disseminated intravascular coagulation in patients with acute and chronic leukemiaAntithrombin III for critically ill patientsRecent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.Sepsis and disseminated intravascular coagulationAntithrombin in the treatment of burn traumaPAMPs and DAMPs as triggers for DICProposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and HemostasisCoagulation abnormalities in critically ill patientsAnticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.Hemostatic abnormalities in critically ill patients.[Therapy with blood products].Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis modelCombination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational studyA multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis.A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsisNew diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study.The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patientsPostoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgeryThrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases.A non-lethal traumatic/hemorrhagic insult strongly modulates the compartment-specific PAI-1 response in the subsequent polymicrobial sepsis.Thrombomodulin in the management of acute cholangitis-induced disseminated intravascular coagulation.Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal?The Japanese guidelines for the management of sepsis.Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation.Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis.Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulationInteractions between coagulation and complement--their role in inflammationDisseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study.Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis.Studies on therapeutic effects and pathological features of an antithrombin preparation in septic disseminated intravascular coagulation patients.Effects of anticoagulant strategies on activation of inflammation and coagulation.Use of antithrombin and thrombomodulin in the management of disseminated intravascular coagulation in patients with acute cholangitis.Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in JapanComplexity of complement activation in sepsis.Thromboelastometry for the assessment of coagulation abnormalities in early and established adult sepsis: a prospective cohort study.Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity.Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis.Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology.Historical perspective and future direction of coagulation research.
P2860
Q24186159-E34C0749-E8D5-4BF9-9B1E-F1C2C7D8430EQ24187024-AECEDDC1-514D-4391-80EA-FE6C36131F9CQ24242053-95FB24A3-0741-4C9D-AC84-7618DEF46FE9Q25255548-DEAEF93A-2774-4E54-B4EC-732237257AA3Q26751555-3CE925EF-55AD-4B79-AAAE-BCF63E078419Q26768246-D37974EC-08B8-4A3E-A0A7-541D284E6A31Q27013790-1A72F750-65BB-44F7-B152-8697A7A35260Q28076449-96212255-6918-447F-9DC0-520A80E66FA3Q28199912-15F9D2BE-6AE0-45D0-A0AF-1257562239FDQ33409966-EA10A950-3370-4A25-8BD6-3F30C740E9F8Q33419474-67CDF035-F171-4605-A4CC-1E78ADA50728Q33429614-E324601A-A936-46BF-8152-F0A756F37E84Q33612689-5EDAAEDB-4267-4AB0-B2AD-D91664A4FC61Q33750809-099B26A2-55D1-4991-8421-36F7DD56211AQ33752182-5F19FA52-B304-40D4-8427-D1505ABDDD51Q33753012-7F74AB12-EF3A-4FB7-B6D2-7B9C1C4E55B6Q33754477-F6617B95-7056-4B18-BC0F-A9DC139AFA41Q34257657-7ABC05A4-50B6-4661-852D-0C15AD6B8E48Q34441153-7D1A5633-7DCC-483E-B974-B6771A071655Q34501341-7F40B478-F1A1-4DA9-9AFE-2D80542922F8Q34586083-CF64DC51-3E90-40AA-9BAE-D205509F51A2Q34932581-8C5C91E5-EB50-436E-B740-6DD652642E84Q35091715-5F511A58-70E5-41A7-A665-179815B502CFQ35107094-B301D67A-8E33-4608-9D63-F5CB161926D9Q35107098-71AEC7CE-3C2F-47A5-BB57-B102427E156BQ35629861-1E4832B7-468E-4A73-B097-8B580F465429Q35829030-4725F3ED-64D8-41FF-97CA-E4D42337B084Q36022738-03BAD7B9-F0C2-4B54-9FC7-F5A01C7738EDQ36073044-07BCAA52-BE15-444D-B73C-89B3690C67F4Q36423261-2DB57C26-D891-486A-AEE2-4A3282E714E0Q36793063-91F3C16A-F69F-4F64-A2AF-7E44D8CEBFEBQ36842724-18156D82-EBAC-4E44-A47F-6F4D06503BCCQ36868752-BFB87511-EEF3-4F55-87D9-585A65ED4512Q37138741-95C39A2A-C93E-43F8-BA5F-6EE1A20CA31EQ37170093-79DC95AB-C9EA-48BE-AD06-C6EC6E3BF542Q37210089-8A309848-FB22-45AF-A2E8-1740F7C4F73CQ37258045-379EDEA0-0638-4619-8932-8F7C0EA96CECQ37697849-0A5EA022-9E33-46D3-B79B-37EF63633020Q37805910-26D9BE36-8534-4840-AE78-2E10AFAF7658Q37903961-05654719-6D0E-4F31-B77B-DF229FEC98BE
P2860
Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Treatment effects of high-dose ...... ted intravascular coagulation.
@en
Treatment effects of high-dose ...... ted intravascular coagulation.
@nl
type
label
Treatment effects of high-dose ...... ted intravascular coagulation.
@en
Treatment effects of high-dose ...... ted intravascular coagulation.
@nl
prefLabel
Treatment effects of high-dose ...... ted intravascular coagulation.
@en
Treatment effects of high-dose ...... ted intravascular coagulation.
@nl
P2093
P2860
P1476
Treatment effects of high-dose ...... ted intravascular coagulation.
@en
P2093
B L Warren
C J Wiedermann
H Ostermann
H-O Keinecke
J N Hoffmann
KyberSept investigators
P2860
P356
10.1111/J.1538-7836.2005.01697.X
P577
2006-01-01T00:00:00Z